176 related articles for article (PubMed ID: 38339343)
61. Targeting Sphingosine Kinase Isoforms Effectively Reduces Growth and Survival of Neoplastic Mast Cells With D816V-KIT.
Bandara G; Muñoz-Cano R; Tobío A; Yin Y; Komarow HD; Desai A; Metcalfe DD; Olivera A
Front Immunol; 2018; 9():631. PubMed ID: 29643855
[TBL] [Abstract][Full Text] [Related]
62. Expression of activated STAT5 in neoplastic mast cells in systemic mastocytosis: subcellular distribution and role of the transforming oncoprotein KIT D816V.
Baumgartner C; Cerny-Reiterer S; Sonneck K; Mayerhofer M; Gleixner KV; Fritz R; Kerenyi M; Boudot C; Gouilleux F; Kornfeld JW; Sillaber C; Moriggl R; Valent P
Am J Pathol; 2009 Dec; 175(6):2416-29. PubMed ID: 19893034
[TBL] [Abstract][Full Text] [Related]
63. Pathogenesis, clinical features, and treatment advances in mastocytosis.
Pardanani A; Akin C; Valent P
Best Pract Res Clin Haematol; 2006; 19(3):595-615. PubMed ID: 16781490
[TBL] [Abstract][Full Text] [Related]
64. Tyrosine kinase inhibitors in the treatment of systemic mastocytosis.
Ustun C; DeRemer DL; Akin C
Leuk Res; 2011 Sep; 35(9):1143-52. PubMed ID: 21641642
[TBL] [Abstract][Full Text] [Related]
65. Sensitive detection of KIT D816V in patients with mastocytosis.
Tan A; Westerman D; McArthur GA; Lynch K; Waring P; Dobrovic A
Clin Chem; 2006 Dec; 52(12):2250-7. PubMed ID: 17040960
[TBL] [Abstract][Full Text] [Related]
66. Mastocytosis and related entities: a practical roadmap.
Beyens M; Elst J; van der Poorten ML; Van Gasse A; Toscano A; Verlinden A; Vermeulen K; Maes MB; Oude Elberink JNGH; Ebo D; Sabato V
Acta Clin Belg; 2023 Aug; 78(4):325-335. PubMed ID: 36259506
[TBL] [Abstract][Full Text] [Related]
67. An immature immunophenotype of bone marrow mast cells predicts for multilineage D816V KIT mutation in systemic mastocytosis.
Teodosio C; García-Montero AC; Jara-Acevedo M; Alvarez-Twose I; Sánchez-Muñoz L; Almeida J; Morgado JM; Matito A; Escribano L; Orfao A
Leukemia; 2012 May; 26(5):951-8. PubMed ID: 22051531
[TBL] [Abstract][Full Text] [Related]
68. Diagnosis and management of mastocytosis: an emerging challenge in applied hematology.
Valent P
Hematology Am Soc Hematol Educ Program; 2015; 2015():98-105. PubMed ID: 26637707
[TBL] [Abstract][Full Text] [Related]
69. Systemic mastocytosis is uncommon in KIT D816V mutation positive core-binding factor acute myeloid leukemia.
Kristensen T; Preiss B; Broesby-Olsen S; Vestergaard H; Friis L; Møller MB
Leuk Lymphoma; 2012 Jul; 53(7):1338-44. PubMed ID: 22145956
[TBL] [Abstract][Full Text] [Related]
70. KIT D816V mutation-positive cell fractions in lesional skin biopsies from adults with systemic mastocytosis.
Kristensen T; Broesby-Olsen S; Vestergaard H; Bindslev-Jensen C; Møller MB
Dermatology; 2013; 226(3):233-7. PubMed ID: 23774045
[TBL] [Abstract][Full Text] [Related]
71. Variable presence of KITD816V in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD).
Sotlar K; Colak S; Bache A; Berezowska S; Krokowski M; Bültmann B; Valent P; Horny HP
J Pathol; 2010 Apr; 220(5):586-95. PubMed ID: 20112369
[TBL] [Abstract][Full Text] [Related]
72. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation.
Gotlib J; Berubé C; Growney JD; Chen CC; George TI; Williams C; Kajiguchi T; Ruan J; Lilleberg SL; Durocher JA; Lichy JH; Wang Y; Cohen PS; Arber DA; Heinrich MC; Neckers L; Galli SJ; Gilliland DG; Coutré SE
Blood; 2005 Oct; 106(8):2865-70. PubMed ID: 15972446
[TBL] [Abstract][Full Text] [Related]
73. Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study.
Hochhaus A; Baccarani M; Giles FJ; le Coutre PD; Müller MC; Reiter A; Santanastasio H; Leung M; Novick S; Kantarjian HM
J Cancer Res Clin Oncol; 2015 Nov; 141(11):2047-60. PubMed ID: 26002753
[TBL] [Abstract][Full Text] [Related]
74. The impact of sensitive KIT D816V detection on recognition of indolent Systemic Mastocytosis.
De Matteis G; Zanotti R; Colarossi S; De Benedittis C; Garcia-Montero A; Bonifacio M; Sartori M; Aprili F; Caruso B; Paviati E; Carli G; Perbellini O; Zamò A; Bonadonna P; Pizzolo G; Guidi G; Martinelli G; Soverini S
Leuk Res; 2015 Mar; 39(3):273-8. PubMed ID: 25582384
[TBL] [Abstract][Full Text] [Related]
75. Next-generation sequencing in systemic mastocytosis: Derivation of a mutation-augmented clinical prognostic model for survival.
Pardanani A; Lasho T; Elala Y; Wassie E; Finke C; Reichard KK; Chen D; Hanson CA; Ketterling RP; Tefferi A
Am J Hematol; 2016 Sep; 91(9):888-93. PubMed ID: 27214377
[TBL] [Abstract][Full Text] [Related]
76. Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis.
Kluin-Nelemans HC; Jawhar M; Reiter A; van Anrooij B; Gotlib J; Hartmann K; Illerhaus A; Oude Elberink HNG; Gorska A; Niedoszytko M; Lange M; Scaffidi L; Zanotti R; Bonadonna P; Perkins C; Elena C; Malcovati L; Shoumariyeh K; von Bubnoff N; Müller S; Triggiani M; Parente R; Schwaab J; Kundi M; Fortina AB; Caroppo F; Brockow K; Zink A; Fuchs D; Angelova-Fischer I; Yavuz AS; Doubek M; Mattsson M; Hagglund H; Panse J; Simonowski A; Sabato V; Schug T; Jentzsch M; Breynaert C; Várkonyi J; Kennedy V; Hermine O; Rossignol J; Arock M; Valent P; Sperr WR
Theranostics; 2021; 11(1):292-303. PubMed ID: 33391475
[TBL] [Abstract][Full Text] [Related]
77. Targeted Treatment Options in Mastocytosis.
Vaes M; Benghiat FS; Hermine O
Front Med (Lausanne); 2017; 4():110. PubMed ID: 28775983
[TBL] [Abstract][Full Text] [Related]
78. Identification of oncostatin M as a STAT5-dependent mediator of bone marrow remodeling in KIT D816V-positive systemic mastocytosis.
Hoermann G; Cerny-Reiterer S; Perné A; Klauser M; Hoetzenecker K; Klein K; Müllauer L; Gröger M; Nijman SM; Klepetko W; Valent P; Mayerhofer M
Am J Pathol; 2011 May; 178(5):2344-56. PubMed ID: 21457934
[TBL] [Abstract][Full Text] [Related]
79. KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib.
Gleixner KV; Mayerhofer M; Cerny-Reiterer S; Hörmann G; Rix U; Bennett KL; Hadzijusufovic E; Meyer RA; Pickl WF; Gotlib J; Horny HP; Reiter A; Mitterbauer-Hohendanner G; Superti-Furga G; Valent P
Blood; 2011 Aug; 118(7):1885-98. PubMed ID: 21680801
[TBL] [Abstract][Full Text] [Related]
80. Recent Advances in the Molecular Biology of Systemic Mastocytosis: Implications for Diagnosis, Prognosis, and Therapy.
Martelli M; Monaldi C; De Santis S; Bruno S; Mancini M; Cavo M; Soverini S
Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32498255
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
